The Biochem Engineering Special Interest Group (BESIG), part of IChemE, is holding its annual technical meeting at the Manchester Institute of Biotechnology, John Garside Building, Princess St, Manchester M1 7DN on 7 July 2022.
Overview
The past decade has seen rapid drug discovery and manufacturing development, as more sophisticated toolboxes have been invented. As a result, new biological modalities, including RNA therapeutics, protein degraders, cyclopeptides, antibody-drug conjugates, and gene therapy, to mention but a few, are maturing at a fast pace. One pertinent example is the life-saving development of the SARS-CoV-2 mRNA vaccines, which has helped illustrate the potential of these emerging biological modalities. Also, mainstream adoption is accelerating as these biological modalities become applicable to previously undruggable indications.
Consequently, as these platforms churn out first-in-class and best-in-class therapies, new challenges arise in development for the clinic and beyond. Some of the main factors influencing drug design and manufacture are patient size, therapeutic index, toxicity, regulation, route of administration and more.
This meeting aims to tackle some of the challenges of developing these emerging biological modalities. Areas of interest such as personalised medicine, digitisation, scale-up, facility design, and automation will be discussed.
Abstracts
Early career researchers are invited to apply to present at this event. Please submit an application.
Time
10:00–17:00 BST, followed by drinks reception.
Price
IChemE member rate (including VAT): £90.00
Non-member rate (including VAT): £140.00
IChemE Student rate (including VAT): Free
Non-member Student rate (including VAT): £30.00